Initial positive first-hand experience of acute keratoconus treatment using platelet-rich serums

Abstract

Presentation of a clinical case of acute keratoconus treatment by the intracameral platelet-rich plasma administration. Clinical and morphological improvement was registered from the first postoperative day, corneal edema and bullous changes completely resolved during 3 weeks. No side effects were observed. The outcome is confirmed by anterior segment optical coherence tomography data Intracameral platelet-rich autologous plasma administration is a safe and effective method of acute keratoconus treatment.

Keywords

autologous serum / cornea / platelet-rich serum / acute keratoconus

References

[1] Alio JL, Toprak I, Rodriguez AE. Treatment of severe keratoconus hydrops with intracameral platelet-rich plasma injection. Cornea. 2019;38(12):1595-1598. https://doi.org/10.1097/ICO.0000000000002070

[2] Слонимский Ю.Б., Слонимский А.Ю. Hydrops corneae. Дифференциальная диагностика и лечение // Вестник Оренбургского государственного университета. – 2014. – № 12. – С. 276–281. [Slonimskiy YuB, Slonimskiy AYu. Hydrops corneae. Differencial diagnosis and treatment. Vestnik of the Orenburg state university. 2014;(12):276–281. (In Russ.)]

[3] Каспаров А.А., Каспарова Е.А., Павлюк А.С. Локальная экспресс-аутоцитокинотерапия (комплекс цитокинов) в лечении вирусных и невирусных поражений глаз // Вестник офтальмологии. – 2004. – T. 120. – № 1. – С. 29–32. [Kasparov AA, Kasparova EA, Pavliuk AS. Local express-autocytocinetherapy (a complex of cytokines) in the treatment of viral and virus-free eye lesions. The Russian annals of ophthalmology. 2014;120(1): 29-32. (In Russ.)]

[4] Патент РФ на изобретение RU № 2165747 С1. Каспаров А.А., Каспарова Е.А., Павлюк А.С. Способ лечения поствоспалительной буллёзной кератопатии. [Patent RUS № 2165747 S1. Kasparov AA, Kasparova EA, Pavlyuk AS. Sposob lecheniya postvospalitel’noy bullyoznoy keratopatii. (In Russ.)] Доступно по: https://yandex.ru/patents/doc/RU2165747C1_20010427. Ссылка активна на 13.07.2020.

[5] Патент РФ на изобретение RU № 2357743 C1. Каспаров А.А., Каспарова Е.А., Павлюк А.С. Средство для лечения, способ получения средства для лечения и способ лечения отёка роговицы и других проявлений ранней буллёзной кератопатии. [Patent RUS № 2357743 S1. Kasparov AA, Kasparova EA, Pavlyuk AS. Sredstvo dlya lecheniya, sposob polucheniya sredstva dlya lecheniya i sposob lecheniya oteka rogovitsy i drugikh proyavleniy ranney bulleznoy keratopatii. (In Russ.)] Доступно по: https://patentinform.ru/inventions/reg-2357743.html. Ссылка активна на 13.07.2020.

[6] Астахов С.Ю., Рикс И.А., Папанян С.С., и др. Опыт клинического применения персонализированной клеточной терапии для лечения больных с первичной эндотелиальной дистрофией после факоэмульсификации // Офтальмологические ведомости. – 2017. – Т. 10. – № 4. – С. 6–12. [Astakhov SYu, Riks IA, Papanyan SS, et al. Experience in personalized cell therapy clinical implementation for treatment of patients with primary endothelial dystrophy after phacoemulsification. Ophthalmology journal. 2017;10(4):6-12. (In Russ.)] https://doi.org/10.17816/ OV1046-12

[7] Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. E Thromb Haemost. 2004;91(1):4-15. https://doi.org/10.1160/TH03-07-0440

[8] Anitua E, Muruzabal F, Tayebbaet A, et al. Autologous serum and plasmarich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93(8):605-614. https://doi.org/10.1111/aos.12710

[9] Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67. https://doi.org/10.1186/scrt218

[10] Lopez-Garcia JS, García-Lozano I, Rivaset L, et al. [Use of autologous serum in ophthalmic practice. (In Spanish)]. Arch Soc Esp Oftalmol. 2007;82(1):9-20. https://doi.org/10.4321/s0365-66912007000100004

[11] Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984-1989. https://doi.org/10.1016/S0161-6420(99)90412-8

[12] Yamada N, Yanai R, Nakamura M, et al. Role of the C domain of IGFs in synergistic promotion, with a substance P-derived peptide, of rabbit corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2004;45(4):1125-1131. https://doi.org/10.1167/iovs.03-0626

[13] Федосеева Е.В., Ченцова Е.В., Боровкова Н.В., и др. Морфофункциональные особенности плазмы, богатой тромбоцитами, и ее применение в офтальмологии // Офтальмология. – 2018. – Т. 15. – № 4. – С. 388–393. [Fedoseeva EV, Chentsova EV, Borovkova NV, et al. Morphofunctional peculiarities of platelet rich plasma and its application in ophthalmology. Ophthalmology in Russia. 2018;15(4):388-393. (In Russ.)] https://doi.org/10.18008/1816-5095-2018-4-388-393

[14] López-Plandolit S, Morales MC, Freire V, et al. Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea. 2011;30(12):1312-1317. https://doi.org/10.1097/ICO.0b013e31820d86d6

[15] Giannaccare G, Versura P, Buzzi M, et al. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci. 2017;56(4):595-604. https://doi.org/10.1016/j.transci.2017.07.023

[16] García-Conca V, Abad-Collado M, Hueso-Abancens JR, et al. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol. 2019;97(2):170-178. https://doi.org/10.1111/aos.13907

[17] Alio JL, Arnalich-Montiel F, Rodriguez AE. The role of «eye platelet rich plasma» (E-Prp) for wound healing in ophthalmology. Curr Pharm Biotechnol. 2012;13(7):1257-1265. https://doi.org/10.2174/138920112800624355

[18] Lee JH, Kim MJ, Ha SW, Kim HK. Autologous platelet-rich plasma eye drops in the treatment of recurrent corneal erosions. Korean J Ophthalmol. 2016;30(2):101-107. https://doi.org/10.3341/kjo.2016.30.2.101

[19] Gehring S, Hoerauf H, Laqua H, et al. Preparation of autologous platelets for the ophthalmologic treatment of macular holes. Transfusion. 1999;39(2):144-148. https://doi.org/10.1046/j.1537-2995.1999.39299154727.x

[20] Figueroa MS, Govetto A, de Arriba-Palomero P. Short-term results of platelet-rich plasma as adjuvant to 23-G vitrectomy in the treatment of high myopic macular holes. Eur J Ophthalmol. 2016;26(5):491-496. https://doi.org/10.5301/ejo.5000729

[21] Abdalrahman O, Rodriguez AE, del Barrio JL, Alio JL. Treatment of chronic and extreme ocular hypotension following glaucoma surgery with intraocular platelet-rich plasma: a case report. Eur J Ophthalmol. 2019;29(4):9-12. https://doi.org/10.1177/1120672118803515

[22] Абугова Т.Д. Клиническая классификация первичного кератоконуса // Современная оптометрия. – 2010. – № 5. – С. 17–20. [Abugova TD. Clinical classifications of primary keratoconus. Sovremennaya optometriya. 2010;(5):17-20. (In Russ.)] https://doi.org/10.17686/sced_rusnauka_2015-179

RIGHTS & PERMISSIONS

Khripun K.V., Kobinets Y.V., Rozhdestvenskaya E.S.